Lp(a ) – Talk Bio

Lilly’s Lepodisiran Shows Durable Lipoprotein(a) Reduction in Phase 2 Trial

3 weeks ago talkbio0Tagged Cardiovascular Diseases, Interferes with, Lepodisiran, long-acting therapy, Lp(a ), RNA

lepodisiran, lipoprotein(a), Lp(a), cardiovascular disease, RNA interference, long-acting therapy

Merck Acquires Rights to Hengrui’s Oral Lp(a) Inhibitor in $2B Deal

4 weeks ago talkbio0Tagged Arteriosclerosis, Cardiovascular Diseases, Hengrui Pharmaceuticals, HRS-5346, licensing agreement, Lp(a ), Merck

Merck, Hengrui Pharmaceuticals, HRS-5346, Lp(a) inhibitor, cardiovascular disease, atherosclerosis, licensing agreement

Breakthrough in Heart Disease Treatment: Lilly’s Muvalaplin and Silence Therapeutics’ Zerlasiran Show Promising Results in Lowering Lipoprotein(a) Levels

5 months ago talkbio0Tagged Atherosclerosis, Cardiovascular system, Gene Silencing Therapy, Heart Disease, Interferes with, Lipoprotein(a ), Lp(a ), Muvalaplin, Risk, RNA, zerlasiran

Lipoprotein(a) (Lp(a)), Heart Disease, Muvalaplin, Zerlasiran, Cardiovascular Risk, Gene Silencing Therapy, RNA Interference, Atherosclerotic Cardiovascular Disease

Lilly’s Muvalaplin Shows Promising Results in Reducing Lipoprotein(a) Levels in Adults at High Risk for Cardiovascular Events

5 months ago talkbio0Tagged Cardiovascular system, cholesterol, Eli, Eli Lilly, Lipoprotein(a ), Lp(a ), Muvalaplin, oral drug, Phase 2 Clinical Trials, Risk

Muvalaplin, Lipoprotein(a) [Lp(a)], Cardiovascular risk, Oral drug, Phase II trial, Eli Lilly, Cholesterol reduction

Silence’s siRNA therapy maintains Lp(a) lowering in cardiovascular study

10 months ago talkbio0Tagged Cardiovascular Diseases, Lp(a ), RNA, Small Interfering

Lp(a ), RNA, Small Interfering, Cardiovascular Diseases